UA112326C2 - Засоби, що викликають апоптоз, для лікування злоякісних новоутворень і імунних і аутоімунних захворювань - Google Patents

Засоби, що викликають апоптоз, для лікування злоякісних новоутворень і імунних і аутоімунних захворювань

Info

Publication number
UA112326C2
UA112326C2 UAA201405088A UAA201405088A UA112326C2 UA 112326 C2 UA112326 C2 UA 112326C2 UA A201405088 A UAA201405088 A UA A201405088A UA A201405088 A UAA201405088 A UA A201405088A UA 112326 C2 UA112326 C2 UA 112326C2
Authority
UA
Ukraine
Prior art keywords
immune
treatment
autoimmune diseases
malignant neoplasms
apoptosis causes
Prior art date
Application number
UAA201405088A
Other languages
English (en)
Inventor
Ле Ван
Джордж Доуерті
Сілу Ван
Чжи-фу ТАО
Мілан Бранко
Аарон Р. КАНЗЕР
Майкл Д. Уендт
Сяохун СУН
Робін Фрей
Тодд М. ХАНСЕН
Джерард М. Салліван
Ендрю Джадд
Ендрю Сауерс
Original Assignee
Еббві Інк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2012/059717 external-priority patent/WO2013055895A1/en
Application filed by Еббві Інк. filed Critical Еббві Інк.
Publication of UA112326C2 publication Critical patent/UA112326C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Описані сполуки, які інгібують активність антиапоптотичних білків Bcl-xL, композиції, що містять сполуки, і способи лікування захворювань, під час яких експресуються антиапоптотичні білки Bcl-xL.
UAA201405088A 2011-10-14 2012-11-10 Засоби, що викликають апоптоз, для лікування злоякісних новоутворень і імунних і аутоімунних захворювань UA112326C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161547165P 2011-10-14 2011-10-14
PCT/US2012/059717 WO2013055895A1 (en) 2011-10-14 2012-10-11 Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases

Publications (1)

Publication Number Publication Date
UA112326C2 true UA112326C2 (uk) 2016-08-25

Family

ID=48086389

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201405088A UA112326C2 (uk) 2011-10-14 2012-11-10 Засоби, що викликають апоптоз, для лікування злоякісних новоутворень і імунних і аутоімунних захворювань

Country Status (5)

Country Link
US (6) US8940737B2 (uk)
CN (1) CN103958508B (uk)
CR (1) CR20140226A (uk)
GT (1) GT201400066A (uk)
UA (1) UA112326C2 (uk)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140189897A1 (en) 2011-06-21 2014-07-03 Mayo Foundation For Medical Education And Research Transgenic animals capable of being induced to delete senescent cells
US8940737B2 (en) 2011-10-14 2015-01-27 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
CN103987711B (zh) 2011-10-14 2016-08-24 艾伯维公司 作为用于治疗癌症和免疫性和自身免疫性疾病的凋亡诱导剂的8-氨基甲酰基-2-(2,3-二取代吡啶-6-基)-1,2,3,4-四氢异喹啉衍生物
KR20140119023A (ko) 2011-12-13 2014-10-08 버크 인스티튜트 포 리서치 온 에이징 의료 요법을 개선하는 방법
US20150064137A1 (en) 2012-04-17 2015-03-05 Kythera Biopharmaceuticals, Inc. Use of engineered viruses to specifically kill senescent cells
US9901081B2 (en) 2012-08-23 2018-02-27 Buck Institute For Research On Aging Transgenic mouse for determining the role of senescent cells in cancer
US9901080B2 (en) 2012-08-23 2018-02-27 Buck Institute For Research On Aging Transgenic mouse having a transgene that converts a prodrug into a cytotoxic compound in senescent cells
AU2015211021B2 (en) 2014-01-28 2020-07-02 Buck Institute For Research On Aging Methods and compositions for killing senescent cells and for treating senescence-associated diseases and disorders
US10328058B2 (en) 2014-01-28 2019-06-25 Mayo Foundation For Medical Education And Research Treating atherosclerosis by removing senescent foam cell macrophages from atherosclerotic plaques
US20190269675A1 (en) 2014-01-28 2019-09-05 Buck Institute for Research and Aging Treatment of parkinson's disease and other conditions caused or mediated by senescent astrocytes using small molecule senolytic agents
US20170216286A1 (en) 2014-01-28 2017-08-03 Mayo Foundation For Medical Education And Research Killing senescent cells and treating senescence-associated conditions using a src inhibitor and a flavonoid
KR102359214B1 (ko) 2014-04-04 2022-02-07 델 마 파마슈티컬스 폐의 비소세포 암종 및 난소암을 치료하기 위한 디안하이드로갈락티톨 및 이의 유사체 또는 유도체
BR112017012342A2 (pt) * 2014-12-09 2018-02-27 Abbvie Inc compostos inibitórios de bcl-xl e conjugados de anticorpo-fármaco incluindo os mesmos
US10195213B2 (en) 2015-03-13 2019-02-05 Unity Biotechnology, Inc. Chemical entities that kill senescent cells for use in treating age-related disease
JP6936498B2 (ja) * 2016-04-21 2021-09-15 バイオベンチャーズ・リミテッド・ライアビリティ・カンパニーＢｉｏＶｅｎｔｕｒｅｓ， ＬＬＣ 抗アポトーシス性Ｂｃｌ−２ファミリータンパク質の分解を誘導する化合物及びその使用
BR112018075639A2 (pt) * 2016-06-08 2019-04-09 Abbvie Inc. conjugados de anticorpo fármaco anti-egfr
CN109912655B (zh) * 2017-12-13 2021-12-10 上海科技大学 Alk蛋白降解剂及其抗肿瘤应用
EP3743069B1 (en) 2018-01-22 2025-08-06 BioVentures, LLC Bcl-2 proteins degraders for cancer treatment
US12559449B2 (en) 2019-05-10 2026-02-24 Zhejiang Hisun Pharmaceutical Co., Ltd. Aromatic ring or heteroaromatic ring derivatives, preparation method therefor and use thereof
CN113509605B (zh) * 2021-07-14 2022-09-20 江苏赛腾医疗科技有限公司 膜式氧合器
KR20250029121A (ko) * 2022-06-24 2025-03-04 난징 레주 테라퓨틱스, 아이엔씨. 벤조티아졸 화합물 및 이의 용도
WO2025130875A1 (zh) * 2023-12-18 2025-06-26 南京瑞初医药有限公司 氮杂环化合物及其应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2332756A1 (fr) 1975-11-26 1977-06-24 Squibb & Sons Inc Nouvelles 1, 4-benzoxazin-3(4h)-ones
DE19929785A1 (de) 1999-06-29 2001-01-04 Bayer Ag Tetrahydrochinolinyl-6-methyldihydrothiadiazinon-Derivate und ihre Verwendung
JP2003521543A (ja) 2000-02-07 2003-07-15 アボット ゲーエムベーハー ウント カンパニー カーゲー ２−ベンゾチアゾリル尿素誘導体およびそのプロテインキナーゼ阻害剤としての使用
BR0112883A (pt) 2000-08-01 2003-06-24 Ono Pharmaceutical Co Composto de derivado de 3,4-diidroisoquinolina e um agente farmacêutico compreendendo o mesmo como ingrediente ativo
AU2002305769B2 (en) * 2001-05-30 2007-07-19 Georgetown University Small molecule antagonists of Bcl2 family proteins
AU2003249713A1 (en) 2002-07-03 2004-01-23 Axys Pharmaceuticals, Inc. 3,4-dihydroisoquinolin-1-one derivatives as inducers of apoptosis
EP1667981A4 (en) 2003-09-23 2008-08-13 Merck & Co Inc ISOCHINOLINE AS KALIUM CHANNEL INHIBITORS
MX2009011210A (es) 2007-04-16 2009-10-30 Abbott Lab Inhibidores de mcl1 de indol 7-no sustituido.
US20090039553A1 (en) 2007-08-10 2009-02-12 3M Innovative Properties Company Microstructured surface molding method
AU2007359392A1 (en) 2007-09-27 2009-04-02 The Walter And Eliza Hall Institute Of Medical Research Benzothiazole compounds
WO2009105746A2 (en) * 2008-02-22 2009-08-27 University Of South Florida Triazoles and processes for producing the same
US20100160322A1 (en) 2008-12-04 2010-06-24 Abbott Laboratories Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
UA108193C2 (uk) 2008-12-04 2015-04-10 Апоптозіндукуючий засіб для лікування раку і імунних і аутоімунних захворювань
US8557983B2 (en) 2008-12-04 2013-10-15 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
RU2561109C2 (ru) 2008-12-19 2015-08-20 Дженентек, Инк. Соединения и способы применения
US8232273B2 (en) 2008-12-19 2012-07-31 Genentech, Inc. Heterocyclic compounds and methods of use
US8546399B2 (en) 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
US9034875B2 (en) 2009-05-26 2015-05-19 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
NZ595708A (en) 2009-05-26 2014-03-28 Abbvie Bahamas Ltd Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US8940737B2 (en) 2011-10-14 2015-01-27 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
CN103987711B (zh) 2011-10-14 2016-08-24 艾伯维公司 作为用于治疗癌症和免疫性和自身免疫性疾病的凋亡诱导剂的8-氨基甲酰基-2-(2,3-二取代吡啶-6-基)-1,2,3,4-四氢异喹啉衍生物
WO2014028381A1 (en) 2012-08-13 2014-02-20 Abbvie Inc. Apoptosis-inducing agents

Also Published As

Publication number Publication date
CN103958508A (zh) 2014-07-30
US9877958B2 (en) 2018-01-30
CR20140226A (es) 2014-07-17
US20180221363A1 (en) 2018-08-09
US20160206611A1 (en) 2016-07-21
GT201400066A (es) 2015-03-23
US9266877B2 (en) 2016-02-23
US20210346369A1 (en) 2021-11-11
US20150152097A1 (en) 2015-06-04
US20130096121A1 (en) 2013-04-18
CN103958508B (zh) 2019-02-12
US8940737B2 (en) 2015-01-27
US20200345717A1 (en) 2020-11-05

Similar Documents

Publication Publication Date Title
UA112326C2 (uk) Засоби, що викликають апоптоз, для лікування злоякісних новоутворень і імунних і аутоімунних захворювань
MY178821A (en) Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
UY34382A (es) Agentes inductores de la apoptosis que pueden usarse para tratar el cáncer y las enfermedades inmunes y autoinmunes
MX337104B (es) Agentes inductores de apoptosis para el tratamiento de cancer y enfermedades inmunes y autoinmunes.
ECSP14000606A (es) Agentes inductores de la apoptosis que pueden usarse para tratar el cáncer y las enfermedades inmunes y autoinmunes
ECSP12012349A (es) Agentes inductores de apoptosis contra el cáncer y de enfermedades inmunes y autoinmunes
EA201890754A1 (ru) Соединения и способы их применения
EA201590997A1 (ru) Соединения и способы их применения
MX360172B (es) Agentes que inducen la apoptosis.
MX371108B (es) Pirimidopirimidinonas utiles como iniciadores de wee-1 cinasa.
MX366804B (es) Translocaciones de la r-espondina y sus metodos de uso.
UA106640C2 (uk) Bcl-2-СЕЛЕКТИВНИЙ АПОПТОЗІНДУКУЮЧИЙ ЗАСІБ ДЛЯ ЛІКУВАННЯ РАКУ І ІМУННИХ ЗАХВОРЮВАНЬ
EA201490423A1 (ru) СПОСОБЫ И КОМПОЗИЦИИ, ОТНОСЯЩИЕСЯ К p62, ДЛЯ ЛЕЧЕНИЯ И ПРОФИЛАКТИКИ РАКА
MX2015003701A (es) Composiciones para tratamiento.
UA110170C2 (uk) Селективні до bcl-2 агенти, які викликають апоптоз, для лікування раку і імунних захворювань